Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of “Hold” by Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been given a consensus recommendation of “Hold” by the five ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $7.30.

Several equities analysts have weighed in on ESPR shares. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, December 12th. Finally, The Goldman Sachs Group started coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock.

Esperion Therapeutics Stock Up 2.7 %

NASDAQ ESPR opened at $2.30 on Wednesday. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The company has a market capitalization of $453.18 million, a P/E ratio of -3.59 and a beta of 1.01. The stock’s 50-day moving average price is $2.42 and its 200-day moving average price is $2.22.

Institutional Trading of Esperion Therapeutics

A number of large investors have recently added to or reduced their stakes in ESPR. BOKF NA bought a new stake in Esperion Therapeutics in the second quarter worth $26,000. Traphagen Investment Advisors LLC purchased a new position in shares of Esperion Therapeutics in the 3rd quarter worth $27,000. Xponance Inc. bought a new stake in shares of Esperion Therapeutics in the 2nd quarter worth about $28,000. National Bank of Canada FI raised its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new position in shares of Esperion Therapeutics in the 2nd quarter valued at about $44,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.